A stock that got absolutely body-slammed
Carl Zeiss Meditec is being pitched as a Strong Buy with a €75 per share target, which is a fancy way of saying: after a 60% share price collapse, someone thinks the market may have gone a little too hard with the pessimism. You know the vibe — when a stock gets beaten down so much that even a mediocre quarter starts looking like a comeback story.
The bad news is real, but maybe not fatal
The rough patch isn’t imaginary. The bearish case centers on:
- Weakness in China, which has been dragging on demand
- An unfavorable product mix, which can crimp profitability
- FX headwinds, because currency swings love to show up uninvited
But the note argues the core business isn’t falling apart. Operating expenses are said to be stable, non-China APAC trends are looking better, and the company still seems to have a decent moat instead of a cardboard fort.
Why investors might still care
The big question isn’t whether the stock has had a rough year — it clearly has. It’s whether the current pain is cyclical, fixable, and already priced in. The note says there’s minimal bankruptcy risk, no guidance to lean on, and a longer-term path for AEPS to reach €2.4 by 2028–2029.
That’s the kind of setup that can turn into a slow-burn recovery trade if the operating picture stabilizes. Or it can stay in the penalty box if China refuses to cooperate. Big picture: this is less “perfect company” and more “market may have overreacted, now prove it.”